- Home
- RGP vs PBYI Comparison
RGP vs PBYI Comparison
Compare RGP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- PBYI
- Stock Information
- Founded
- RGP 1996
- PBYI 2010
- Country
- RGP United States
- PBYI United States
- Employees
- RGP N/A
- PBYI N/A
- Industry
- RGP Business Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- RGP Consumer Discretionary
- PBYI Health Care
- Exchange
- RGP Nasdaq
- PBYI Nasdaq
- Market Cap
- RGP 155.0M
- PBYI 171.7M
- IPO Year
- RGP 2006
- PBYI N/A
- Fundamental
- Price
- RGP $4.72
- PBYI $5.31
- Analyst Decision
- RGP Sell
- PBYI Strong Buy
- Analyst Count
- RGP 1
- PBYI 1
- Target Price
- RGP $5.00
- PBYI $7.00
- AVG Volume (30 Days)
- RGP 338.0K
- PBYI 696.9K
- Earning Date
- RGP 09-30-2025
- PBYI 08-07-2025
- Dividend Yield
- RGP 5.89%
- PBYI N/A
- EPS Growth
- RGP N/A
- PBYI 434.29
- EPS
- RGP N/A
- PBYI 0.97
- Revenue
- RGP $551,331,000.00
- PBYI $238,062,000.00
- Revenue This Year
- RGP N/A
- PBYI N/A
- Revenue Next Year
- RGP $20.14
- PBYI N/A
- P/E Ratio
- RGP N/A
- PBYI $5.48
- Revenue Growth
- RGP N/A
- PBYI 8.63
- 52 Week Low
- RGP $4.44
- PBYI $2.23
- 52 Week High
- RGP $10.45
- PBYI $5.45
- Technical
- Relative Strength Index (RSI)
- RGP 42.85
- PBYI 86.63
- Support Level
- RGP $4.44
- PBYI $3.05
- Resistance Level
- RGP $4.94
- PBYI $5.44
- Average True Range (ATR)
- RGP 0.24
- PBYI 0.31
- MACD
- RGP -0.01
- PBYI 0.25
- Stochastic Oscillator
- RGP 21.37
- PBYI 94.61
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.